Gliomatosis cerebri other imaging findings: Difference between revisions
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
Other imaging studies for gliomatosis cerebri include [[In vivo magnetic resonance spectroscopy|MR spectroscopy]] (elevated [[choline]]/[[creatine]] ratio, [[choline]]/[[N-Acetylaspartic acid|NAA]] ratio, and [[myo-inositol|myoinositol]]), [[perfusion weighted imaging|MR perfusion]] (low/normal relative cerebral blood flow), [[PET scan]] (markedly decreased accumulation of [[Florbetapir (18F)|[18F]-fluorodeoxyglucose | Other imaging studies for gliomatosis cerebri include [[In vivo magnetic resonance spectroscopy|MR spectroscopy]] (elevated [[choline]]/[[creatine]] ratio, [[choline]]/[[N-Acetylaspartic acid|NAA]] ratio, and [[myo-inositol|myoinositol]]), [[perfusion weighted imaging|MR perfusion]] (low/normal relative cerebral blood flow), [[PET scan]] (markedly decreased accumulation of [[Florbetapir (18F)|[18F]-fluorodeoxyglucose]] on [[PET|F-18 FDG PET]] images, hypermetabolism on [[PET|C-11 methionine PET]] images, and marked increase in cerebral blood flow on [[PET|15(O)-water PET]] images), and [[bone scan]] (metastasis to bones).<ref name=aaa>Radiographic features of gliomatosis cerebri. Dr Henry Knipe and Dr Frank Gaillard et al. Radiopaedia 2015. http://radiopaedia.org/articles/gliomatosis-cerebri</ref> | ||
===1. MR Spectroscopy=== | ===1. MR Spectroscopy=== | ||
Revision as of 18:38, 2 October 2015
|
Gliomatosis cerebri Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Gliomatosis cerebri other imaging findings On the Web |
|
American Roentgen Ray Society Images of Gliomatosis cerebri other imaging findings |
|
Risk calculators and risk factors for Gliomatosis cerebri other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Other imaging studies for gliomatosis cerebri include MR spectroscopy (elevated choline/creatine ratio, choline/NAA ratio, and myoinositol), MR perfusion (low/normal relative cerebral blood flow), PET scan (markedly decreased accumulation of [18F]-fluorodeoxyglucose on F-18 FDG PET images, hypermetabolism on C-11 methionine PET images, and marked increase in cerebral blood flow on 15(O)-water PET images), and bone scan (metastasis to bones).[1]
Other Imaging Findings
Other imaging studies for gliomatosis cerebri include MR spectroscopy (elevated choline/creatine ratio, choline/NAA ratio, and myoinositol), MR perfusion (low/normal relative cerebral blood flow), PET scan (markedly decreased accumulation of [18F]-fluorodeoxyglucose on F-18 FDG PET images, hypermetabolism on C-11 methionine PET images, and marked increase in cerebral blood flow on 15(O)-water PET images), and bone scan (metastasis to bones).[1]
1. MR Spectroscopy
Other imaging studies for gliomatosis cerebri include MR spectroscopy. Common findings are described below:[1]
- Elevated choline/creatine ratio
- Elevated choline/NAA ratio
- Marked elevation of myoinositol
2. MR Perfusion
Other imaging studies for gliomatosis cerebri include MR perfusion. Common findings are described below:[1]
- Low/normal relative cerebral blood flow (no vascular hyperplasia)
3. PET
Other imaging studies for gliomatosis cerebri include PET scan. Common features are described below:[1]
- F-18 FDG PET images show markedly decreased accumulation of [18F]-fluorodeoxyglucose (glucose hypometabolism).
- C-11 methionine PET images show hypermetabolism.
- 15(O)-water PET images show a marked increase in cerebral blood flow in gliomatosis cerebri lesions.
4. Bone Scan
Bone scan may be performed to detect metastases of gliomatosis cerebri to bones.
References